Wells Fargo & Company Vigil Neuroscience, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.68 - $3.63 $1,953 - $2,646	729 Added 14.8%	5,655 $19,000
Q4 2023 Feb 09, 2024	BUY	$2.97 - $8.6 $2,892 - $8,376	974 Added 24.65%	4,926 $16,000
Q3 2023 Nov 13, 2023	SELL	$4.8 - $9.92 $10,291 - $21,268	-2,144 Reduced 35.17%	3,952 $21,000
Q2 2023 Aug 15, 2023	BUY	$8.11 - $10.54 $48,741 - $63,345	6,010 Added 6988.37%	6,096 $57,000
Q1 2023 May 12, 2023	BUY	$8.77 - $12.7 $8 - $12	1 Added 1.18%	86 $0
Q4 2022 Feb 13, 2023	BUY	$8.74 - $15.99 $270 - $495	31 Added 57.41%	85 $1,000
Q3 2022 Nov 14, 2022	BUY	$2.37 - $9.61 $16 - $67	7 Added 14.89%	54 $0
Q2 2022 Aug 12, 2022	SELL	$2.23 - $7.81 $3,162 - $11,074	-1,418 Reduced 96.79%	47 $0
Q1 2022 May 16, 2022	BUY	$7.03 - $17.29 $10,298 - $25,329	1,465 New	1,465 $10,000

26.3M

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $94.1M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.